Jacques Besnainou

Executive Advisor to the CEO

Pittsburgh, Pennsylvania, United States

About

At Westinghouse, I support the company’s global commercial strategy to deliver integrated enterprise-wide solutions and deepen customer relationships. With 40 years of experience in the global nuclear and energy industries, I have held global executive roles with progressive expansion at the AREVA Group where I led the Back-End Business Group and the growth of the North American business. Before AREVA, I successfully developed and sold Ecobilan, an innovative start-up, specializing in life cycle analysis. More recently, I was President of Kurion, Inc, served on the board of General Fusion and provided executive consulting and strategic counsel across the energy and nuclear industries. In 2013, I proudly achieved the promise I made to my mother when I was a child and she was losing her battle with cancer. Researching, writing and publishing her story as a ‘hidden’ child in France during World War II, I chronicle the struggles and survival of two families – my mother’s and my mother-in-law’s. Titled "The Promise," my novel is now published and available on Amazon (paperback and Kindle). It is also available in French, published under the title: "Ma promesse". More information can be found at the following website: www.jacquespromise.com.

Experience

  • Westinghouse Electric Company ()
    • Executive Advisor to the CEO
      Jan 2026 - Present · 7 mos

    • Chief Commercial Officer
      Jul 2022 - Dec 2025 · 3 yrs 6 mos

  • Laborde Energy Law Center Advisory Council Member at Louisiana State University
    Feb 2014 - Present · 12 yrs 6 mos

  • Conseiller at Les Conseillers du Commerce extérieur de la France
    Jan 1999 - Jul 2024 · 25 yrs 7 mos

  • Chairman Of The Board at Zeffy
    Jan 2020 - Jun 2022 · 2 yrs 6 mos

    Zeffy is an innovative platform offering 100% free online fundraising tools for Nonprofit Organizations.

  • Board Member at Orano Med (formerly AREVA Med)
    Dec 2017 - Jun 2022 · 4 yrs 7 mos

    Orano Med has developed new processes for producing high-purity lead-212 (212Pb), a rare radioactive isotope. 212Pb is currently at the heart of promising research projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells.